Over the last decades, we have witnessed an extraordinary explosion of scientific breakthroughs that have been successfully applied in many areas of research. In particular, rapid developments in fields such as medicine, biology, chemistry and related disciplines provides an unprecedented opportunity for scientists to be involved in this scientific revolution and enthusiastically contribute to it with life-changing discoveries. This accelerated evolution has led to an exponentially increased number of published research articles. Although there has been a surprisingly high number of newly launched journals in the last several years (trying to keep up with the increasing number of submitted research manuscripts), only a small fraction of these journals are ISI/PubMed indexed and have meaningful impact factors. Only few journals can be considered as high impact factor and very few of the recently launched journals have reached this stage. Moreover, there is an even smaller number of new high quality multidisciplinary journals covering more than one area of research. An increasing need for interdisciplinary approaches makes publication of high quality, innovative and reproducible papers in non-multidisciplinary journals sometimes challenging.
With a dismal acceptance rate of less than 8% in some of the top multidisciplinary journals, such as Science, Nature, other journals from the Nature family, the New England Journal of Medicine [1-3] many of the cutting-edge discoveries not accepted for publication end up being re-submitted (frequently multiple times) to a lower impact factor journal, most of the time a more specialized one. In addition, a low acceptance rate also makes the reviewing process prone to subjectivity and may result in outstanding manuscripts being rejected. Thus, we consider that new high impact platforms for publishing high-quality interdisciplinary/ multidisciplinary research and cutting edge discoverries are very much needed.
Why is the submission process so cumbersome?
The need for innovation:
1. Why does a manuscript have a specific format before it is even accepted? Many manuscripts submitted in a specific format requested by a particular journal are eventually rejected. For a journal with an acceptance rate of less than 8%, the vast majority of the manuscripts will subsequently be submitted to an alternative journal, with different formatting requirements. In fact, many manuscripts are submitted to several journals before they are finally accepted. Thus, the authors spend considerable and unnecessary time modifying the format of the manuscript every time when they submit it to a different journal. We believe that this cumbersome and multi-step submission process increases the submission time more than is necessary. Our solution is simple and straight forward: allow submission of manuscripts in different formats and only request the re-formatting for those accepted, after reviewing process is finalized.
Would it not

Why not utilize a rapid and simple submission process?
We believe that an easy and simplified submission process will be well received by authors.
Why not allow authors to submit their manuscripts with only minimal necessary information in less than a few minutes? In addition, why not complete the additional agreements or other information that is requested after acceptance? What is the point of submitting a Cover Letter with a letterhead and signature by the corresponding author when that author can just conveniently write the same text and send it in an e-mail (with or without an electronic signature) or can submit it as a text on the submission platform?
Is a Cover Letter really necessary? Do we really need a Cover Letter, when we have the Abstract and Conclusions of a manuscript in front of us? Many editors and reviewers consider a Cover
Letter useful, since it is easier for them to get a quick general idea about the scope and importance of the manuscript. Authors may consider that the Cover Letter is a way of highlighting their discoveries and significance of their findings. However, in our opinion, it is faster, easier and without significant consequences for authors to submit a manuscript without a Cover Letter, as long as the innovation, novelty, and importance of their findings is well underscored in the Abstract and Conclusion sections of the manuscript. Thus, we think that the Cover Letter should be optional.
Are rules for validation of key antibodies, siRNAs, and other reagents employed essential?
Antibodies, other reagents, inadequate animal models or cell-based models/assays, insufficient number of experimental repeats and statistical inadequacies all contribute to the low reproducibility of preclinical and clinical data [4] [5] [6] [7] [8] . Thus, adequate measures and rules for reagents defined by the journals would be of great help in decreasing the number of reported irreproducible research findings.
A recent study pointed out that many of the antibodies used in publications are non-specific and some of them do not even detect endogenous target proteins in multiple cell lines [4] . The authors should employ knockdown or knockout validation experiments to confirm the specificity of the employed antibodies. Thus, requesting proofs of the specificity of the main/key antibodies used in the manuscript would be of great help. These proofs may be the experiments performed by the authors themselves, results already published or validation experiments done by the manufacturer. Also, it is worth mentioning a recent initiative for Independent Antibody Validation to Improve Research Quality [9] . Manufacturers and researchers can send antibodies to be validated by an independent laboratory.
Due to the numerous off-target effects of siRNA or shRNAs widely used in preclinical biomedical research, rescue experiments, or at least two different types of siRNA/shRNAs for the same target, need to be used. Many journals, reviewers or editors still accept manuscripts that employ only one siRNA/shRNA.
These are only two important examples. Several journals, such as those published by American Association for Cancer Research, already have rules for validation of antibodies and other reagents [10] .
Therefore, the articles submitted to Discoveries are expected to describe work undertaken only with critical reagents that have been validated using one of the manners suggested above, or accompanied by other convincing scientific evidence about their effects.
Is there a need for new scientific research rules and for joining existing initiatives?
We want to highlight the importance of using standards in scientific research, such as the definition of cell death and classificasion of all cell death types [11] [12] [13] . Notable examples are the recommendations on classification of cell death made by Nomenclature Committee on Cell Death (NCCD) [11, 12] . One of the committee's suggestions is to use at least two different methods for detection of apoptosis or other forms of cell death [11] , since it is well established that many of the methods that detect apoptosis may also detect necrosis [13] . A second recommendation is to avoid terminology such as "% apoptosis", "% cell death", or "% survival". Instead, the authors should mention exactly what they have measured by stating the employed method, such as "% cells TUNEL positive", or "% cells Annexin V positive" [11, 13] . This is due to the fact that most of the techniques are not entirely specific for detection of apoptosis, cell death, survival, or proliferation. For example, MTT/MTS assays are considered methods that can measure survival, proliferation, or a combination of survival and proliferation, while Annexin V staining alone can detect not only apoptosis, but also nonapoptotic cell death, such as necrosis [13] . NCCD "urges" all scientific journals to join NCCD and Cell Death and Differentiation journal's initiative in adopting these recommendations. [11, 13] . Similar initiatives and recommendations are needed in many other areas of research.
Can we avoid requesting unnecessary experiments during the reviewing process?
How many of the experiments suggested by the reviewers/editor are indeed necessary to accept a manuscript? The answer to this question depends on many variables, including the standards of the journal and the quality of the experiments presented in the manuscript. The myth of the complete paper enlists effort from entire laboratories so that a complete paper is eventually published, rather than one experimental observation that would be sufficient in itself to advance the field and benefit others. Not so uncommonly, in such papers the valuable data are still those at the core of the main experimental observation. As recently suggested by Professor Hidde Ploegh from Harvard Medical School in a recent article published in Nature [14] , [14] . Some of the reviewers may feel the need to ask for additional experiments, even though these experiments do not change the overall results or conclusions of the manuscript.
As previously suggested [14] , one solution is to select editors with expertise and ability to decide which of the experiments suggested by the reviewers are indeed necessary. Another useful measure would be to ask the reviewers to suggest only critical experiments addressing the validity of the manuscript's conclusions (and to state what points of the manuscript are clarified by the requested experiments), avoiding unnecessary work that could be included in a future project. Discoveries is committed to implement these measures.
7. Can we break the "glass ceiling" that excludes human materials studies from high impact journals? Translation of mechanistic studies from tissue culture or model organisms into human subjects is perhaps one of the most daunting challenges in biomedical research. In vivo studies in people (i.e. clinical trials) require significant preclinical work in model organisms but the "single figure" that aims to show relevance of a model study to humans is often poorly designed and described, especially with respect to clinical parameters of tissue donors. On the other hand, many studies with human subjects materials are relegated to relatively low impact journals and are difficult to assess by readers due to the lack of important controls, lack of subject matching and other technical weaknesses. Other studies that exclusively analyze human materials are published in modestly perceived journals due to their focus on characterization, even if such papers are destined to be widely cited by, for example, rodent studies that hunger for human relevance. Overall, the difficulties of human studies, which include recruitment challenges amidst the need for high numbers of samples to account for genetic variability, are insufficiently offset by publication in lower impact journals, where even strong human studies are generally mixed in with non-human studies of lower technical value. Sometimes human studies that provide critical foundations for years of preclinical work are published in similarly obscure journals due to lack of mechanistic or in vivo approaches. These limitations do not reward welldesigned human studies that are absolutely critical to move fields forward, and to prevent surprises once clinical trials seem justified. High quality research on human subjects materials is absolutely essential to support top human materials research, which is a critical segue from the avalanche of models studies waiting to be proven applicable to the clinic.
Therefore, Discoveries will also consider manuscripts describing research involving human materials studies. 
